PTPN11 and Insulin resistance: The advent of genetically engineered animal models, aiming at suppressing SHP2 expression or expressing hyperactive mutants in specific tissues or organs, allowed documenting the metabolic impact of its targeted dysfunction and further supported a protective role for SHP2 in insulin resistance.